Marco D. Dibonaventura
Holistic Medicine
1000 Valley Forge Cir Ste 105
King Of Prussia, PA 19406
King Of Prussia, PA 19406
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 110 publications
Cost-effectiveness analysis of elranatamab versus physician's choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan.
Journal: Journal of medical economics
Published: September 08, 2026
Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies.
Journal: Future oncology (London, England)
Published: April 23, 2026
Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.
Journal: Future oncology (London, England)
Published: April 13, 2026
Real-World Treatment Patterns of Elranatamab in Patients with Multiple Myeloma in Japan: The EVEREST Study.
Journal: ClinicoEconomics and outcomes research : CEOR
Published: November 18, 2025
The impact of reduced dosing frequency of elranatamab on patient-reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-3.
Journal: HemaSphere
Published: April 24, 2025
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma.
Journal: Blood and lymphatic cancer : targets and therapy
Published: February 06, 2025
Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data.
Journal: Current medical research and opinion
Published: March 25, 2024
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma.
Journal: Future oncology (London, England)
Published: February 28, 2024
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3.
Journal: British journal of haematology
Published: November 16, 2023
Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
Journal: American journal of clinical dermatology
Published: July 20, 2023
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Journal: American journal of clinical dermatology
Published: April 11, 2023
Last Updated: 09/26/2026